These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38721949)

  • 1. Stressful life events, psychiatric comorbidities and serum neuromediator levels in patients with chronic spontaneous urticaria treated with omalizumab.
    Elçin A; Ayla G; Tuba Saadet Deveci B; Özlem G; Murat Ö; Ahmet Selim B; Behçet C
    Allergol Immunopathol (Madr); 2024; 52(3):1-7. PubMed ID: 38721949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria.
    Boyvadoglu C; Ulusal H; Taysı S; Ozaydin-Yavuz G; Yavuz IH; Korkmaz P; Inaloz HS
    Mediators Inflamm; 2023; 2023():8087274. PubMed ID: 37795408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
    Can PK; Etikan P; Degirmentepe EN; Kocaturk E
    Asian Pac J Allergy Immunol; 2024 Jun; 42(2):132-137. PubMed ID: 33638627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
    Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
    Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impacts of Omalizumab on the Psychiatric Comorbidities of Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
    Tan MG; Bailey AMJ; Dorus B; Kirchhof MG
    J Drugs Dermatol; 2024 Apr; 23(4):e116-e117. PubMed ID: 38564395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
    Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
    Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
    [No Abstract]   [Full Text] [Related]  

  • 11. IFN-γ/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy.
    Grieco T; Porzia A; Paolino G; Chello C; Sernicola A; Faina V; Carnicelli G; Moliterni E; Mainiero F
    Int J Dermatol; 2020 May; 59(5):590-594. PubMed ID: 32048727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
    ; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
    Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.
    Bostan E; Zaid F; Karaduman A; Dogan S; Gulseren D; Yalici-Armagan B; Akdogan N; Ersoy-Evans S; Elcin G
    J Cosmet Dermatol; 2021 Nov; 20(11):3369-3375. PubMed ID: 34599630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
    Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
    Front Immunol; 2021; 12():635069. PubMed ID: 33737936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
    Zubiaga-Fernandez L; Testera-Montes A; Rondon C; Perez-Sanchez N; Gomez-Perez F; Vega-Chicote JM; Bartra J; Ferrer M; Eguiluz-Gracia I; Torres MJ
    Clin Exp Allergy; 2024 Jun; 54(6):402-411. PubMed ID: 38343206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
    Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
    Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
    Cakmak ME; Yeğit OO; Öztop N
    Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
    Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
    Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
    Farrah G; Stevenson B; Lie K; Brusch A
    Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.